IL205290A - A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs - Google Patents

A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs

Info

Publication number
IL205290A
IL205290A IL205290A IL20529010A IL205290A IL 205290 A IL205290 A IL 205290A IL 205290 A IL205290 A IL 205290A IL 20529010 A IL20529010 A IL 20529010A IL 205290 A IL205290 A IL 205290A
Authority
IL
Israel
Prior art keywords
medicaments
therapy
variant
manufacture
pharmaceutical compositions
Prior art date
Application number
IL205290A
Other languages
English (en)
Hebrew (he)
Other versions
IL205290A0 (en
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Publication of IL205290A0 publication Critical patent/IL205290A0/en
Publication of IL205290A publication Critical patent/IL205290A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL205290A 2007-11-05 2010-04-22 A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs IL205290A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07021493 2007-11-05
PCT/EP2008/009320 WO2009059755A2 (en) 2007-11-05 2008-11-05 Novel neurturin conjugates for pharmaceutical use

Publications (2)

Publication Number Publication Date
IL205290A0 IL205290A0 (en) 2010-12-30
IL205290A true IL205290A (en) 2014-01-30

Family

ID=40521395

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205290A IL205290A (en) 2007-11-05 2010-04-22 A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs

Country Status (17)

Country Link
US (3) US9029323B2 (enExample)
EP (1) EP2217282A2 (enExample)
JP (2) JP2011503019A (enExample)
KR (2) KR20100098619A (enExample)
CN (2) CN104288775A (enExample)
AU (1) AU2008324426B2 (enExample)
BR (1) BRPI0819220A2 (enExample)
CA (1) CA2742839A1 (enExample)
CO (1) CO6280503A2 (enExample)
CR (1) CR11406A (enExample)
EA (1) EA201070484A1 (enExample)
IL (1) IL205290A (enExample)
MX (1) MX2010004899A (enExample)
NZ (1) NZ585262A (enExample)
SG (1) SG185946A1 (enExample)
WO (1) WO2009059755A2 (enExample)
ZA (1) ZA201003227B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
JP4838724B2 (ja) 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
BR112012009801A8 (pt) * 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US8742677B2 (en) * 2010-01-11 2014-06-03 System General Corp. LED drive circuit with a programmable input for LED lighting
CN102453725B (zh) * 2010-11-02 2014-06-11 杭州纽龙生物科技有限公司 一种重组载体、包含该重组载体的重组菌株及制备方法
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
JP2003524381A (ja) * 1998-09-22 2003-08-19 ユニヴァーシティ オブ メリーランド，ボルチモア システインノット成長因子ミュータント
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
EP2275118A3 (en) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
AU2004283053A1 (en) * 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
JP4838724B2 (ja) 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin

Also Published As

Publication number Publication date
WO2009059755A3 (en) 2009-09-24
CN101848735B (zh) 2014-07-23
EA201070484A1 (ru) 2011-04-29
US20110003741A1 (en) 2011-01-06
JP2011503019A (ja) 2011-01-27
EP2217282A2 (en) 2010-08-18
KR20150139982A (ko) 2015-12-14
SG185946A1 (en) 2012-12-28
CR11406A (es) 2010-10-25
WO2009059755A2 (en) 2009-05-14
NZ585262A (en) 2012-06-29
CN104288775A (zh) 2015-01-21
US20160060317A1 (en) 2016-03-03
BRPI0819220A2 (pt) 2019-02-26
IL205290A0 (en) 2010-12-30
US9029323B2 (en) 2015-05-12
AU2008324426B2 (en) 2014-03-27
MX2010004899A (es) 2010-09-07
CA2742839A1 (en) 2009-05-14
KR20100098619A (ko) 2010-09-08
AU2008324426A1 (en) 2009-05-14
ZA201003227B (en) 2011-03-30
CO6280503A2 (es) 2011-05-20
CN101848735A (zh) 2010-09-29
JP2015057384A (ja) 2015-03-26
US20130231283A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
IL222880A (en) Peptides and their use in the treatment and diagnosis of diseases and pharmaceutical preparations containing them
IL197420A (en) Polymorphic form of 4 - [3 - (4 - cyclopropanecarbonyl - piperazine - 1 - carbonyl) - 4 - fluoro - benzyl] - h2 - phthalazine - 1 - on, methods of preparation, a pharmaceutical preparation containing it and uses in this form to prepare drugs for the treatment of the human body
IL193678A (en) Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity
IL199835A (en) Acid-activated antimicrobial peptides, their pharmaceutical preparations, and their use in drug preparation
IL202840A (en) Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disorders
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
IL191310A (en) A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL197442A (en) Therapeutic compositions containing glp-elp fusion proteins and their use in preparing a drug
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
IL202379A (en) Benzoxaborols, their pharmaceutical preparations and their use in the preparation of bacteria to inhibit the growth of germs
IL197441A (en) @ Polymer @ and @@ box – a @@ hmgb strains or a wild variety or its active biological components, medicinal preparations containing them and their use in the preparation of drugs for the prevention or treatment of related pathologies to @ hmgbA
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
IL193094A (en) Appalidine and other drugs used in the manufacture of a cancer treatment drug when the combination of the two gives a synergistic result
IL200278A (en) Use of aclidinium for the manufacture of a drug for use in the treatment or prevention of respiratory illness and pharmacist's preparation for the treatment or prevention of respiratory illness
IL200947A (en) Desprithiocine polyether analogues and their use in the preparation of drugs for the treatment of diseases
PT2083837E (pt) Utilização terapêutica de pelo menos uma neurotoxina botulínica no tratamento da dor induzida por, pelo menos, um agente anti-cancerígeno
IL203986A0 (en) Cdh3 peptide and medicinal agent comprising the same
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees